Top

Pharmaceutical Capsule Manufacturing – Progesterone 100MG

Active

Federal

Response Deadline08/21/2026, 05:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN FSGBView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedJul 22

subcontract

Response DeadlineAug 21

Submission deadline

Response Deadline

08/21/2026, 05:00:00 PM UTCin 28 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN FSGB

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Defense → MEDICAL SUPPLY CHAIN FSGB

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Manufacture of Progesterone 100MG capsules in 100-count bottles compliant with FDA cGMP, DSCSA, and therapeutic equivalence 'A' rating.

Similar Contracts

Same NAICS industry code

NAICS: 325412

New

DIBBS

TEST STRIPS AND COLORThe contract specifies the procurement of urine test strips and color charts capable of detecting bilirubin, blood, glucose, ketone, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen, each packaged in bottles of 100 strips per unit, with a total quantity of two units required. The items must comply with stringent technical and quality requirements referenced from the DLA Master List of Technical and Quality Requirements and are subject to medical packaging standards, including compliance with Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must ensure protection against damage and safe delivery via common carriers at the lowest cost, with all labels clearly displaying the date of manufacture, expiration date, contract number, and lot number in accordance with MMS1C guidelines. A shelf-life requirement of 18 months is mandatory and non-extendable, with no more than two months allowed to have elapsed between the date of manufacture and the date of delivery to the government. The items are classified as a TYPE I (CODE K) item under the shelf-life specification, and all labeling must conform to the latest revision of MMS1C. The solicitation number is SPE2DS-26-T-263E, issued on July 23, 2026, with responses due by July 29, 2026, and delivery required within five days of award. The contracting office is under the Department of Defense’s Medical Supply Chain, with Mary-Kathryn Donahue designated as the primary point of contact. The NSN is 6550-01-221-5400, and the NAICS code is 325412, identifying the industry as medical and surgical instrument manufacturing.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

ERYTHROMYCIN OPHTHALMIErythromycin Ophthalmic Ointment, USP, is a sterile topical medication containing 5 mg of erythromycin per gram in a base of mineral oil and white petrolatum, formulated for ophthalmic use as an RX-only product. Each unit is packaged in single-dose tubes containing 3.5 grams of ointment, with a unit of issue consisting of 24 tubes per package. The product has a total shelf life of 36 months, and upon receipt by the first government activity, it must have a minimum of 31 months of remaining shelf life. Storage requirements specify controlled room temperature between 15°C and 30°C (59°F–86°F), with protection from excessive heat and freezing. All packaging and labeling must strictly conform to Medical Marking Standard No. 1, superseding MIL-STD-129, and commercial packaging must comply with ASTM D3951 unless overridden by DLA’s Master List of Technical and Quality Requirements. The manufacturer is PADAGIS US LLC with NDC 00574-4024-39, and the NSN is 6505-01-189-7090. The contract requires delivery of one package (24 tubes) to Fort Bragg, North Carolina, within 20 days of issuance, with FOB destination and zero tolerance for quantity variance. Delivery must be made via traceable freight methods, excluding parcel post, and packaging must meet all DLA procurement standards including palletization and hazardous material handling per FED-STD-313 where applicable. The item falls under a Type I (Code Q) shelf-life category with a non-extendable 36-month lifespan. The contracting official must submit a referral via EBS to confirm product compliance with FDA regulations, including manufacturer and part number details. The solicitation, issued under SPE2DP-26-T-4260, was posted on July 23, 2026, with a response deadline of July 29, 2026, and the required delivery date is July 14, 2026. All documentation, labeling, and marking must align with DLA’s current technical and quality requirements, and the point of contact for inquiries is James McCullough.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

LORATADINE TABLETSLoratadine tablets 10 mg are being procured in quantities of 2 business units, with each unit containing 500 tablets, for a total of 1,000 tablets under contract SPE2DP-26-T-4248. The product must comply with all technical and quality requirements referenced in the DLA Master List of Technical and Quality Requirements, including packaging and marking standards specified in Medical Marking Standard No. 1, which replaces MIL-STD-129. Packaging must be commercial-grade, with each unit sealed in a container that protects against damage and breakage, and shipped in exterior containers suitable for safe delivery via common carrier at the lowest cost to the destination point. The item is regulated by the FDA and requires storage between 20°C and 25°C (68°F to 77°F), protected from excessive moisture. It has a non-extendable shelf life of 36 months, classified as a TYPE I (CODE Q) item under DLA shelf-life requirements. The manufacturer is OHM Laboratories Inc. with NDC 51660-0526-05, and the distributor is AmerisourceBergen Drug Corp. Delivery is FOB destination within 20 days of contract award with zero tolerance for quantity variance, and inspection and acceptance occur at the delivery point. The NSN is 6505-01-524-9179, and all markings must adhere to the latest MMS No. 1 guidelines available through DLA Troop Support. The contracting official must submit a referral in EBS with manufacturer and bidder details prior to award.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

DEXAMETHASONE TABLETSThe contract pertains to the procurement of Dexamethasone Tablets, USP, 0.5 mg, in unit dose packaging under the National Stock Number 6505-01-045-0451, with a total quantity of 2 packaging groups, each equivalent to 100 tablets. The supplier must adhere to strict packaging and labeling requirements as defined by Medical Marking Standard No. 1, which supersedes MIL-STD-129, and all units must be sealed in protective containers to ensure integrity during shipment. The product, manufactured by Roxane Labs or Hikma Pharmaceuticals USA Inc. under NDC 00054-8179-25, is regulated by the FDA and requires confirmation via EBS referral. It carries a non-extendable shelf life of 36 months and must be marked in full compliance with the latest Medical Marking Standard. Delivery is required FOB destination within five days of contract award, with zero variance allowed in quantity, and inspection and acceptance occur at the destination point. The solicitation is issued under SPE2DP-26-T-4266, with a response deadline of July 29, 2026, and the sole point of contact is James Foggie at DLA Troop Support, with performance directed to Fort Bragg, NC, 28310.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TUBE, EXTENSION, INJEThe item is a 3-way stopcock extension set with 60-inch small bore tubing featuring a male luer lock connection, designed for injection procedures, with a priming volume of 1.3 mL and packaged in quantities of 25 units per package. The product is identified by NSN 6515-01-550-8492 and is being procured under solicitation SPE2DS-26-T-268C, with a response deadline of July 29, 2026, and a delivery requirement of 20 days after award. The specification includes technical and quality requirements referenced in the DLA Master List, and packaging must comply with DLA standards, including the removal of government identification from non-accepted supplies. The contract is managed by the Department of Defense through the Medical Supply Chain MD Surg FSF office, with performance required at Fort Bliss, Texas, and point of contact information provided for inquiries.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

RINGER'S INJECTION, LACRINGER'S INJECTION LACTATED USP in 1000 mL units, packaged 12 per pack (1 PG), is procured under contract SPE2DP-26-T-4258 with a total quantity of 21 packs to be delivered within 20 days FOB destination. The product is regulated by the FDA and carries a non-extendable shelf life of 30 months as a TYPE I (CODE P) item. Packaging must comply with Medical Marking Standard No. 1, replacing all prior references to MIL-STD-129, and must ensure protection from damage and breakage during transit. Units must be packed in commercial exterior shipping containers suitable for safe delivery at the lowest carrier rate, with labeling and marking strictly following the latest version of MMS No. 1. The product must be stored at room temperature (25°C), with brief exposure up to 40°C permitted without adverse effects, and must be protected from freezing and excessive heat. The manufacturer is B. BROWN MEDICAL INC with NDC number 00264-7750-00 and part number L7500. Inspection and acceptance occur at the delivery point with zero variance allowed in quantity. All technical and quality requirements are governed by the DLA Master List of Technical and Quality Requirements, with applicable revisions controlled by the solicitation or award date. Government identification must be removed from non-accepted supplies per RQ011, and procurement is subject to covered defense information provisions. Delivery is to Fort Bragg, NC, with primary point of contact Timothy McCauley at DLA.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ALBUMIN HUMANALBUMIN HUMAN USP 25% in 50 mL vials is specified for intravenous use only, with a concentration of 25% volume to volume, and is heat treated with included administration accessories such as 18 or 20 gauge needles. Each unit must be free of turbidity and stored at room temperature, with no freezing allowed. The product has a non-extendable shelf life of 36 months and is classified as a TYPE I (CODE Q) item under shelf-life requirements. It is regulated by the FDA, and buyers must ensure proper referral through EBS to confirm bidder and manufacturer details, including NDC numbers for KEDRION BIOPHARMA INC and GRIFOLS USA LLC. Packaging must comply with Commercial standards as specified in the procurement document, conforming to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and must be contained in sealed, protective unit containers within suitable commercial shipping containers to ensure safe, low-cost delivery to the destination point. All units must be marked and packaged according to MIL-STD-2073-1E, and the material is subject to RD003 covered defense information provisions. The contract calls for a delivery of exactly 10 packs, each containing one 50 mL vial, totaling 500 mL, to be delivered within five days FOB destination with zero variance allowed. Inspection and acceptance occur at the destination. The solicitation number is SPE2DP-26-T-4249, issued by the Department of Defense’s Medical Supply Chain, with a response deadline of July 29, 2026, and performance is designated for Fort Bragg, NC.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

WATER FOR INJECTIONThe contract specifies the procurement of 10 packages of Water for Injection, Sterile, USP, each package containing 25 sterile 20 mL vials with flip-top closures, for a total of 250 vials. The product must comply with USP standards and be labeled in accordance with the latest Medical Marking Standard No. 1, with packaging conforming to MIL-STD-2073-1E. Storage requirements mandate controlled room temperature between 20 and 25 degrees Celsius, and the item has a non-extendable shelf life of 24 months as per RS016 and RS001 for a Type I (Code M) item. The delivery is FOB destination within 20 days of contract award with zero variance allowed in quantity, and inspection and acceptance occur at the destination. The item is regulated by the FDA, and buyers must submit a referral through EBS including manufacturer and bidder details. Only two approved manufacturers are listed: Hospira Worldwide LLC with NDC 00409-4887-20 and Fresenius Kabi, LLC with NDC 63323-0185-20. The contract is issued under solicitation SPE2DP-26-T-4261, with a response deadline of July 29, 2026, and the NSN is 6505-00-582-5079. All technical and quality requirements are governed by the DLA Master List of Technical and Quality Requirements, and provisions for removal of government identification from non-accepted supplies and potential covered defense information apply.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TOLNAFTATE POWDER, UThe contract specifies the procurement of TOLNAFTATE POWDER USP 1% in 45 gram units, identified by NSN 6505014807897 and NDC 57896-0199-45, supplied by GERI-CARE PHARMACEUTICALS CORP. The item is classified as a TYPE I (CODE Q) medical product with a non-extendable shelf life of 36 months and must be packaged in compliance with the DLA Master List of Technical and Quality Requirements, superseding all other standards including ASTM D3951 and MIL-STD-129. Each unit must be sealed in a protective container and shipped in commercial exterior packages suitable for safe delivery via common carrier at the lowest cost, marked in accordance with Medical Marking Standard No. 1, which replaces all prior military marking requirements. The unit of issue is BT, where one BT equals 45 grams, and each shipment must adhere to strict palletization and labeling guidelines outlined in RP001 and other referenced DLA technical directives. The contract includes three separate line items totaling 28 BT (1,260 grams), with delivery deadlines of July 23, 2026, for 24 BT destined to FPO AP 96694, July 27, 2026, for 3 BT to VILSECK, Germany, and one BT to an unspecified location. All deliveries are FOB destination, with zero variance allowed in quantity, inspection and acceptance occurring upon arrival. Shipment must occur via the fastest traceable means, explicitly prohibiting parcel post, and must comply with hazardous material handling requirements per FED-STD-313 and IP025 if applicable. The contract is issued under solicitation SPE2DP-26-T-4256, with a five-day delivery window, and all packaging and labeling requirements must reflect the latest DLA medical standards, ensuring full traceability, regulatory compliance, and readiness for military medical use.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

SODIUM CHLORIDE INJECT

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

SODIUM CHLORIDE INJECT

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

about 19 hours ago

DEADLINE

in 5 days

View Details

More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN FSGB

Same awarding agency

NAICS: 541611

New

DIBBS

Subcontract Management for Commercial Items

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Regulatory Compliance and Quality Assurance

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Labeling and Data Encoding (NDC, Lot, Expiry)

Commercial Printing (except Screen and Books)

POSTED

DEADLINE

Barcode Labeling and Compliance

Commercial Printing (except Screen and Books)

POSTED

DEADLINE

Unit-of-Use Pharmaceutical Packaging

All Other Plastics Product Manufacturing

POSTED

DEADLINE

Pharmaceutical Capsule Manufacturing – Progesterone 200MG

Pharmaceutical Preparation Manufacturing

POSTED

DEADLINE

PHARM MANUF/DISTR DIV - FSAThis contract establishes a nationwide pharmaceutical supply agreement under the Pharmaceutical Prime Vendor (PPV) program, managed by the Defense Logistics Agency Troop Support and the Department of Veterans Affairs, to provide essential medications to the Department of Defense, Veterans Affairs, Bureau of Prisons, and Indian Health Service. The awardee must supply listed pharmaceutical products in accordance with specified quantities estimated in Appendix B, with the contract structured for a one-year base period and four additional option years, totaling a maximum five-year term. Delivery is facilitated through designated PPV contractors, who receive products directly from the awardee and distribute them to government medical facilities; the contractor does not bill the government directly but instead enters into business-to-business agreements with each PPV for payment terms, delivery schedules, and logistics. The contractor is required to have all products registered with RXNorm, First Data Bank, and Medi-Span within five days of award and must comply with strict labeling standards including GS1-128 or HIBCC-compliant barcodes that encode the National Drug Code, lot number, and expiration date, with printing quality meeting ANSI/ISO/IEC Grade C or better. Packaging must feature child-proof closures, meet specific container dimensions, be compatible with automated dispensing systems, and exclude glass bottles. The solicitation is evaluated under a Lowest Price Technically Acceptable (LPTA) methodology, requiring technical acceptability in both compliance with the Statement of Work and demonstrated past performance before price is considered. Offers are deemed technically unacceptable if products lack FDA-approved NDA, ANDA, or BLA status, if manufacturing facilities have unresolved cGMP violations, or if therapeutic equivalence codes are not “A” rated unless all alternatives in the group are “B” rated with submitted bioequivalence data. The contractor must immediately report any FDA warning letters or cGMP inspection failures, and may be restricted from shipping affected products unless granted a 90-day authorization with an approved corrective action plan. Backorders occurring when orders are not fulfilled within 15 days trigger mandatory reporting within four calendar days and may lead to government procurement from alternate vendors, with the contractor liable for any excess costs incurred. The contractor is prohibited from assigning payment rights and cannot initiate claims under the Disputes Clause for disagreements with PPVs. Compliance with the Drug Supply Chain Security Act is mandatory, and adherence to DFARS 252.204-7018 prohibits the use of covered defense telecommunications equipment or services, requiring detailed disclosures of such equipment if applicable. All

Drugs and Druggists' Sundries Merchant Wholesalers

POSTED

DEADLINE

Small Business and Socioeconomic RepresentationThis contract requires accurate representation of small business status and socioeconomic eligibility, including certifications such as Women-Owned Small Business and Service-Disabled Veteran-Owned Small Business, to ensure compliance with federal contracting regulations. Contractors must verify and maintain their eligibility throughout the performance period and provide documentation as needed to substantiate their status. Subcontract reporting obligations may apply depending on contract terms, requiring timely and precise disclosure of all subcontracts awarded under this agreement. The contract falls under NAICS code 541611, which pertains to management consulting services, and is issued by the Department of Defense through the Medical Supply Chain FSGB. It is classified as a subcontract with a submission deadline of August 13, 2026, and was posted on July 13, 2026. While no specific set-aside designation is indicated, participants must still adhere to all applicable small business requirements and reporting standards. The performance location and point of contact details are not specified, and all necessary information can be accessed through the provided DIBBS link.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Cybersecurity and Covered Defense Telecommunications ComplianceThe contract mandates strict compliance with cybersecurity requirements focused on eliminating covered defense telecommunications equipment from all information technology systems, as mandated by DFARS 252.204-7018. Contractors must provide formal certification confirming the absence of any prohibited equipment sourced from specified foreign vendors deemed a national security risk, ensuring the integrity and security of systems handling defense-related data. This obligation applies across all tiers of the supply chain and requires ongoing monitoring and documentation to maintain compliance throughout the contract lifecycle. The contract is structured as a subcontract under the NAICS code 541512 for custom computer programming services, issued by the Department of Defense through the Medical Supply Chain FSGB agency. It has a response deadline of August 13, 2026, with no set-aside provisions or specific geographic performance requirements outlined. All entities seeking to participate must demonstrate complete alignment with the DFARS requirements and be prepared to submit verifiable attestation of compliance, with failure to do so potentially resulting in contract termination or debarment. Access to full details is available via the provided DIBBS portal link.

Computer Systems Design Services

POSTED

DEADLINE

National Drug Code and Regulatory Compliance ManagementThe contract involves the ongoing management of National Drug Code registration, therapeutic equivalence reporting, FDA compliance, and recall execution for pharmaceutical products supplied under the agreement. This subcontract requires consistent adherence to federal regulatory standards to ensure accurate drug identification, proper labeling, and timely reporting of product equivalence data to support pharmacy substitution and regulatory transparency. The contractor must maintain rigorous control over FDA compliance processes and be prepared to execute recalls swiftly and precisely in accordance with institutional and federal protocols to safeguard public health and supply chain integrity. Work under this agreement is tied to the Department of Defense’s Medical Supply Chain FSGB and falls under NAICS code 541611, indicating a focus on administrative management and other support services related to regulatory affairs. The solicitation was posted on July 13, 2026, with responses due by August 13, 2026, and performance is expected to be coordinated across the broader defense healthcare logistics network without specified geographic limitations. The contractor is expected to demonstrate proven expertise in pharmaceutical regulatory operations and maintain continuous alignment with evolving FDA requirements and Defense logistics standards.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Supply of Atorvastatin Calcium 80 MG TabletsThe contract entails the annual supply of 6,633 bottles, each containing 90 tablets of Atorvastatin Calcium 80 MG, totaling nearly 600,000 tablets per year for a five-year period. This high-dose statin is intended for cholesterol management and will be procured under a subcontract arrangement by the Department of Defense through its Medical Supply Chain FSGB. The solicitation was posted on July 13, 2026, with a response deadline set for August 13, 2026, indicating an active procurement cycle targeting manufacturers or distributors capable of meeting the volume and quality requirements. The NAICS code 325412 confirms the involvement of pharmaceutical manufacturing, and while specific delivery locations are not detailed, performance is expected to align with federal supply chain protocols under DOD oversight. The absence of a set-aside designation suggests open competition among qualified vendors.

Pharmaceutical Preparation Manufacturing

POSTED

DEADLINE

Supply of Levothyroxine Sodium 112 MCG TabletsThe contract entails the annual supply of 12,379 bottles, each containing 90 tablets of Levothyroxine Sodium 112 MCG, totaling approximately 1.11 million tablets per year for a five-year period, to support high-volume thyroid hormone replacement therapy needs. This is a subcontract under the Department of Defense’s Medical Supply Chain FSBG, governed by NAICS code 325412 for pharmaceutical preparation manufacturing, with a solicitation window opening on July 13, 2026, and a firm response deadline of August 13, 2026. The product is intended to meet sustained demand within federal healthcare infrastructure, requiring consistent, quality-assured delivery of a critical medication across the contract term. While the place of performance and point of contact details are unspecified, the procurement is publicly accessible via the DIBBS platform for qualified suppliers to respond.

Pharmaceutical Preparation Manufacturing

POSTED

11 days ago

DEADLINE

in 20 days

View Details